Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for TEVIMBRA + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metas...
Takeaways: Health Canada’s CTA clearance positions Affinia among the first wave of next‑gen cardiac gene therapy players, using a bespoke AAV capsid to go after genetically defined BAG...
